Showing results (11-20 of 262) with videos related to
Sort By:
Pageof 27
Expert Review of Clinical Pharmacology|October 25, 2019
Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implicationsFabian Frontzek, Georg LenzLeukemia & Lymphoma|November 2, 2020
The role of PI3K inhibitors in the treatment of malignant lymphomasPhilipp Berning, Georg LenzBlood|December 4, 2019
Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphomaPhilip Bucher, Tabea Erdmann, Paula Grondona, et al.Nature Immunology|March 27, 2019
Safeguard function of PU.1 shapes the inflammatory epigenome of neutrophilsJosephine Fischer, Carolin Walter, Alexander Tönges, et al.Leukemia|November 9, 2022
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphomaWendan Xu, Philipp Berning, Tabea Erdmann, et al.Therapeutic Advances in Hematology|April 5, 2013
The molecular biology of diffuse large B-cell lymphomaMareike Frick, Bernd Dörken, Georg LenzDeutsche Medizinische Wochenschrift (1946)|February 5, 2020
[Current diagnostic and therapeutic standards in aggressive B-cell lymphomas]Birte Friedrichs, Norbert Schmitz, Georg LenzCancer|August 27, 2004
The role of fludarabine in the treatment of follicular and mantle cell lymphomaGeorg Lenz, Wolfgang Hiddemann, Martin DreylingLeukemia & Lymphoma|December 28, 2022
Plasmablastic lymphoma: from genetics to treatmentFabian Frontzek, Stephan Hailfinger, Georg LenzBest Practice & Research. Clinical Haematology|March 14, 2012
New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphomaMareike Frick, Bernd Dörken, Georg LenzPageof 27